Select your country or region to view content specific to your country.
- Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in the Atlanta, GA, United States
- AIOS is the MDx system that integrates Seegene’s liquid handler and real-time PCR instruments.
- Seegene’s MDx system will efficiently access a wide array of Seegene’s syndromic assays.
SEOUL,
Korea (September 23, 2021) – Seegene Inc. (KQ 096530), a leading
biotechnology firm specializing in molecular diagnostics, is unveiling a fully
automated real-time PCR testing (MDx) system at the 2021
AACC Annual Scientific Meeting & Clinical Lab Expo to be held on September
26-30, 2021, in Atlanta, GA, USA.
The
AACC is a premier exposition for clinical laboratory products and services with
73 years of history. This global event invites players of major laboratory
medicine community including 700 global IVD companies. Seegene also has
participated in this event since 2007 along with other global IVD companies.
During this event, Seegene will be unveiling AIOS - its first fully automated MDx system. AIOS provides high-throughput real-time PCR workflow starting from nucleic acid extraction, then, real-time PCR, and finally result interpretation. AIOS is the world’s first fully automated syndromic MDx system designed in a modular concept while it compiles Seegene’s cutting-edge high multiplex real-time PCR technologies.
A noteworthy feature of AIOS is that its MDx system is composed of
independent and detachable modules together with its proprietary SW
architecture. Unlike others’ single-body system, AIOS
is designed with an extraction/liquid handler and
real-time PCR instrument being integrated with an in-house developed robotic
arm module. Hospitals and laboratories can either purchase the full package of ‘AIOS’ system or integrate
their existing instruments on site if they already have Seegene’s liquid
handler and real-time PCR instrument.
Some
of the other highlights include: world’s only ‘high-throughput automated
syndromic MDx system’. It also adopts a variety of Seegene’s assays, that are
currently available on the market, which allows for symptom-based tests. And
finally, it can identify the exact cause of a specific symptom with a single
tube, which will enable both cost- and time- effective tests. Therefore, Seegene
added that AIOS will be
affordable to small-to-medium sized hospitals due to its unique
modular and assay features.
“AIOS represents Seegene’s decades-long
commitment to developing cutting-edge technologies in the molecular diagnostics
field,” said Dr. Jong-Yoon Chun, CEO of Seegene, “I believe AIOS will
contribute to the public health by making MDx more accessible in everyday life.“